AIM CONCEPT INTEGRATION
Viral Hepatitis A, B and C: Pathogenesis, Diagnosis, Treatment and Prevention
4th Year MBBS • GIT Module • KMU Curriculum
Connect transmission → liver injury → clinical disease → diagnosis → treatment and prevention for rapid revision. :contentReference[oaicite:0]{index=0}
1. THE TOPIC IN ONE CONNECTED FLOW
Viral hepatitis begins with exposure to a hepatotropic virus, followed by infection of hepatocytes and mainly immune-mediated liver injury. The route of transmission helps identify the likely virus, while persistence determines whether disease remains acute or progresses to chronic hepatitis, fibrosis, cirrhosis and hepatocellular carcinoma.
Exposure
HAV/HEV: fecal–oral
HBV/HCV: blood or body-fluid exposure
HAV/HEV: fecal–oral
HBV/HCV: blood or body-fluid exposure
→
Hepatocyte Infection
Virus reaches liver → viral antigens trigger host immune response
Virus reaches liver → viral antigens trigger host immune response
→
Liver Injury
Immune-mediated hepatocyte injury → ballooning, apoptosis and inflammation
Immune-mediated hepatocyte injury → ballooning, apoptosis and inflammation
→
Clinical Expression
Fatigue, anorexia, nausea, dark urine, jaundice and raised aminotransferases
Fatigue, anorexia, nausea, dark urine, jaundice and raised aminotransferases
→
Diagnostic Clue
HAV: IgM anti-HAV
HBV: serology + HBV DNA
HCV: HCV RNA
HAV: IgM anti-HAV
HBV: serology + HBV DNA
HCV: HCV RNA
→
Intervention
Support acute disease → suppress HBV → cure HCV with DAAs → prevent exposure
Support acute disease → suppress HBV → cure HCV with DAAs → prevent exposure
→
Outcome
HAV/HEV usually resolve; persistent HBV/HCV → fibrosis, cirrhosis and HCC risk
HAV/HEV usually resolve; persistent HBV/HCV → fibrosis, cirrhosis and HCC risk
Enteric branch:
contaminated food/water → HAV or HEV → acute hepatitis → supportive management and prevention through hygiene, sanitation and exposure control.
contaminated food/water → HAV or HEV → acute hepatitis → supportive management and prevention through hygiene, sanitation and exposure control.
Blood-borne branch:
infected blood/body fluids → HBV or HCV → possible persistence → chronic inflammation and fibrosis → antiviral treatment plus transmission prevention.
infected blood/body fluids → HBV or HCV → possible persistence → chronic inflammation and fibrosis → antiviral treatment plus transmission prevention.
2. KEY CLINICAL CONNECTIONS
Chronic HBV: Pathology → Clinical Risk
Persistent HBV infection
→
interface inflammation and ground-glass hepatocytes
→
progressive fibrosis
→
cirrhosis, portal hypertension and hepatocellular carcinoma risk.
→
interface inflammation and ground-glass hepatocytes
→
progressive fibrosis
→
cirrhosis, portal hypertension and hepatocellular carcinoma risk.
HBV Serology → Stage of Infection
HBsAg present
→
current infection
→
HBV DNA quantifies replication.
→
current infection
→
HBV DNA quantifies replication.
Anti-HBs present
→
immunity
→
anti-HBc distinguishes natural exposure from vaccination.
→
immunity
→
anti-HBc distinguishes natural exposure from vaccination.
Antiviral Target → Clinical Benefit
Tenofovir / entecavir
→
inhibit HBV polymerase
→
reduce viral replication and ongoing liver injury.
→
inhibit HBV polymerase
→
reduce viral replication and ongoing liver injury.
HCV direct-acting antivirals
→
block essential viral proteins
→
eliminate active HCV infection in successfully treated patients.
→
block essential viral proteins
→
eliminate active HCV infection in successfully treated patients.
3. AIM HIGH-YIELD INTEGRATION REVIEW
⭐ Transmission guides the differential: fecal–oral exposure points toward HAV/HEV, whereas blood or body-fluid exposure supports HBV/HCV.
⭐ HBV injury is mainly immune mediated: infected hepatocytes become targets of the host response → inflammation, apoptosis and possible chronic fibrosis.
⭐ HBV serology must be interpreted as a pattern: HBsAg identifies current infection, anti-HBs immunity, anti-HBc natural exposure and HBV DNA active replication.
⭐ HCV antibody is not proof of active infection: anti-HCV shows exposure → detectable HCV RNA confirms current viremia.
Chronic HBV or HCV
→ persistent inflammation → fibrosis → cirrhosis → portal hypertension and hepatocellular carcinoma risk.
→ persistent inflammation → fibrosis → cirrhosis → portal hypertension and hepatocellular carcinoma risk.
Tenofovir and entecavir
→ HBV polymerase inhibition → viral suppression; renal and bone effects are important cautions with tenofovir disoproxil.
→ HBV polymerase inhibition → viral suppression; renal and bone effects are important cautions with tenofovir disoproxil.
HCV direct-acting antivirals
→ inhibition of viral replication proteins → finite therapy and viral clearance; drug interactions and hepatic status influence regimen selection.
→ inhibition of viral replication proteins → finite therapy and viral clearance; drug interactions and hepatic status influence regimen selection.
Prevention acts before chronic damage:
HBV vaccination + safe blood/injection/sexual practices reduce HBV transmission, while HCV control depends mainly on preventing infected blood exposure and treating active infection.
HBV vaccination + safe blood/injection/sexual practices reduce HBV transmission, while HCV control depends mainly on preventing infected blood exposure and treating active infection.
AIM Exam Trap: Anti-HBs alone with negative anti-HBc suggests vaccination, whereas anti-HBs plus anti-HBc indicates recovery after natural HBV infection. During the HBV window period, IgM anti-HBc may be the key positive marker.